How would you approach bone-only metastases in a postmenopausal woman with HR+/HER2+ breast cancer currently on anti-HER2+/AI maintenance?

Initial treatment with Taxane-Trastuzumab-Pertuzumab with then maintenance with the two anti-HER2 agents and and an aromatase inhibitor. Would you biopsy new bone lesions? How would approach use of TDM-1 and/or changing endocrine backbone?

1 Answer

Mednet MemberInvited Expert

Medical Oncology · Warren Alpert Medical School of Brown University

Answered on

If you are convinced that her metastatic disease has progressed on her prior treatment, would consider a couple of options, including T-DM1, presumably with discontinuation of endocrine therapy (am not aware of any studies looking at T-DM1 +/- endocrine therapy in ER+/HER2+ patients). Another option...

Join for free or sign in to see the full answer